GW Pharmaceuticals, Otsuka Announce Results from Two Remaining Sativex Phase 3 Cancer Pain Trials; Consistent With Previously Announced Results from Initial Phase 3 Trial, Remaining Trials Fail to Show Superiority Over Placebo